Login / Signup

Response to Imatinib therapy is inferior for e13a2 BCR-ABL1 transcript type in comparison to e14a2 transcript type in chronic myeloid leukaemia.

Graeme GreenfieldRoss McMullanNuala RobsonJulie McGimpseyMark CatherwoodMary Frances McMullin
Published in: BMC hematology (2019)
Patients with an e13a2 transcript demonstrate an inferior molecular response to imatinib in our regional population.
Keyphrases
  • chronic myeloid leukemia
  • rna seq
  • tyrosine kinase
  • acute lymphoblastic leukemia
  • bone marrow
  • dendritic cells
  • single cell
  • mesenchymal stem cells
  • drug induced
  • smoking cessation
  • cell therapy